Novartis Reports Strong 2025 Financials with Double-Digit Operating Income Growth and Strategic Acquisitions

summarizeSummary

Novartis reported strong 2025 financial results with significant growth in sales and operating income, driven by key innovative products. The company also engaged in substantial strategic acquisitions and increased shareholder returns through buybacks and dividends.

check_boxKey Events

• Strong 2025 Financial Performance

  Net sales from continuing operations grew 8% to $54.5 billion, operating income increased 25% (cc) to $17.6 billion, and basic EPS rose 24% (cc) to $7.21.

• Key Innovative Medicines Drive Growth

  Products like Kisqali (+57% cc), Kesimpta (+36% cc), Pluvicto (+42% cc), Scemblix (+85% cc), and Leqvio (+57% cc) were major contributors to sales growth.

• Strategic Acquisitions and Pipeline Expansion

  Completed acquisitions of Anthos Therapeutics, Regulus Therapeutics, and Tourmaline Bio in 2025, and announced a pending $12 billion acquisition of Avidity Biosciences, strengthening its innovative medicines portfolio.

• Increased Shareholder Returns

  Executed an $8.9 billion share buyback in 2025, initiated a new up-to $10 billion program, and proposed a dividend increase to CHF 3.70 per share.

auto_awesomeAnalysis

Novartis AG delivered robust financial performance in 2025, marked by significant growth in key metrics and strategic expansion. Net sales from continuing operations increased by 8% to $54.5 billion, while operating income surged by 25% in constant currencies to $17.6 billion. Basic earnings per share also saw a substantial rise of 24% in constant currencies to $7.21. This strong growth was primarily fueled by key innovative medicines such as Kisqali, Kesimpta, Pluvicto, Scemblix, and Leqvio, which demonstrated impressive sales momentum. The company actively pursued strategic acquisitions in 2025, including Anthos Therapeutics, Regulus Therapeutics, and Tourmaline Bio, and announced a pending $12 billion acquisition of Avidity Biosciences, reinforcing its focus on innovative medicines. Shareholder returns were prioritized with an $8.9 billion share buyback in 2025 and the announcement of a new $10 billion program, alongside a proposed dividend increase to CHF 3.70 per share. While facing generic competition for products like Entresto and Promacta, Novartis's proactive engagement with the US administration on drug pricing, including a voluntary agreement, helps manage regulatory risks. The company's stock is currently trading near its 52-week high, reflecting investor confidence in its performance and strategic direction.